Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Crazy About Jounce Therapeutics, Inc. (JNCE)

We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Jounce Therapeutics, Inc. (NASDAQ:JNCE) based on that data.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) has seen an increase in enthusiasm from smart money recently. Our calculations also showed that JNCE isn’t among the 30 most popular stocks among hedge funds.

So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the market by 18 percentage points since May 2014 through December 3, 2018 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter. Even if you aren’t comfortable with shorting stocks, you should at least avoid initiating long positions in our short portfolio.

CITADEL INVESTMENT GROUP

Let’s go over the new hedge fund action encompassing Jounce Therapeutics, Inc. (NASDAQ:JNCE).

How have hedgies been trading Jounce Therapeutics, Inc. (NASDAQ:JNCE)?

At Q3’s end, a total of 11 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 10% from the previous quarter. The graph below displays the number of hedge funds with bullish position in JNCE over the last 13 quarters. So, let’s see which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

JNCE_dec2018

Among these funds, Millennium Management held the most valuable stake in Jounce Therapeutics, Inc. (NASDAQ:JNCE), which was worth $4.2 million at the end of the third quarter. On the second spot was EcoR1 Capital which amassed $3.2 million worth of shares. Moreover, Redmile Group, Casdin Capital, and Citadel Investment Group were also bullish on Jounce Therapeutics, Inc. (NASDAQ:JNCE), allocating a large percentage of their portfolios to this stock.

As aggregate interest increased, key money managers have jumped into Jounce Therapeutics, Inc. (NASDAQ:JNCE) headfirst. EcoR1 Capital, managed by Oleg Nodelman, initiated the largest call position in Jounce Therapeutics, Inc. (NASDAQ:JNCE). EcoR1 Capital had $3.2 million invested in the company at the end of the quarter. Noam Gottesman’s GLG Partners also initiated a $1.3 million position during the quarter. The other funds with brand new JNCE positions are Jim Simons’s Renaissance Technologies, D. E. Shaw’s D E Shaw, and Michael Platt and William Reeves’s BlueCrest Capital Mgmt..

Let’s now take a look at hedge fund activity in other stocks similar to Jounce Therapeutics, Inc. (NASDAQ:JNCE). These stocks are RGC Resources, Inc. (NASDAQ:RGCO), Approach Resources Inc. (NASDAQ:AREX), Eaton Vance Municipal Income 2028 Term Trust (NYSE:ETX), and Teligent, Inc. (NASDAQ:TLGT). All of these stocks’ market caps resemble JNCE’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
RGCO 1 296 1
AREX 4 307 0
ETX 1 152 1
TLGT 7 57858 1
Average 3.25 14653 0.75

View table here if you experience formatting issues.

As you can see these stocks had an average of 3.25 hedge funds with bullish positions and the average amount invested in these stocks was $15 million. That figure was $15 million in JNCE’s case. Teligent, Inc. (NASDAQ:TLGT) is the most popular stock in this table. On the other hand RGC Resources, Inc. (NASDAQ:RGCO) and Eaton Vance Municipal Income 2028 Term Trust (NYSE:ETX) are the least popular ones with only 1 bullish hedge fund positions each. Compared to these stocks Jounce Therapeutics, Inc. (NASDAQ:JNCE) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...